Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

Derralynn A Hughes; Kathleen Nicholls; Gere Sunder-Plassmann; Ana Jovanovic; Ulla Feldt-Rasmussen; Raphael Schiffmann; Robert Giugliani; Vipul Jain; Chris Viereck; Jeffrey P Castelli; Nina Skuban; Jay A Barth; Daniel G Bichet

doi:10.1002/ajmg.a.61105

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

Derralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, Ana Jovanovic, Ulla Feldt-Rasmussen, Raphael Schiffmann, Robert Giugliani, Vipul Jain, Chris Viereck, Jeffrey P Castelli, Nina Skuban, Jay A Barth, Daniel G Bichet

Department of Clinical Medicine

4 Citations (Scopus)

18 Downloads (Pure)

Original language	English
Journal	American Journal of Medical Genetics. Part A
Volume	179
Issue number	6
Pages (from-to)	1069-1073
Number of pages	5
ISSN	1552-4825
DOIs	https://doi.org/10.1002/ajmg.a.61105
Publication status	Published - Jun 2019

Access to Document

10.1002/ajmg.a.61105

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyFinal published version, 682 KB

Cite this

Hughes, D. A., Nicholls, K., Sunder-Plassmann, G., Jovanovic, A., Feldt-Rasmussen, U., Schiffmann, R., Giugliani, R., Jain, V., Viereck, C., Castelli, J. P., Skuban, N., Barth, J. A., & Bichet, D. G. (2019). Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. American Journal of Medical Genetics. Part A, 179(6), 1069-1073. https://doi.org/10.1002/ajmg.a.61105

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study. / Hughes, Derralynn A; Nicholls, Kathleen; Sunder-Plassmann, Gere et al.
In: American Journal of Medical Genetics. Part A, Vol. 179, No. 6, 06.2019, p. 1069-1073.

Research output: Contribution to journal › Journal article › Research › peer-review

Hughes, DA, Nicholls, K, Sunder-Plassmann, G, Jovanovic, A, Feldt-Rasmussen, U, Schiffmann, R, Giugliani, R, Jain, V, Viereck, C, Castelli, JP, Skuban, N, Barth, JA & Bichet, DG 2019, 'Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study', American Journal of Medical Genetics. Part A, vol. 179, no. 6, pp. 1069-1073. https://doi.org/10.1002/ajmg.a.61105

@article{ae24c017d70f45d59ce59458f43286eb,

title = "Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study",

author = "Hughes, {Derralynn A} and Kathleen Nicholls and Gere Sunder-Plassmann and Ana Jovanovic and Ulla Feldt-Rasmussen and Raphael Schiffmann and Robert Giugliani and Vipul Jain and Chris Viereck and Castelli, {Jeffrey P} and Nina Skuban and Barth, {Jay A} and Bichet, {Daniel G}",

year = "2019",

month = jun,

doi = "10.1002/ajmg.a.61105",

language = "English",

volume = "179",

pages = "1069--1073",

journal = "American Journal of Medical Genetics. Part A",

issn = "1552-4825",

publisher = "JohnWiley & Sons, Inc.",

number = "6",

}

TY - JOUR

T1 - Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease

T2 - Experience from the Phase 3 ATTRACT study

AU - Hughes, Derralynn A

AU - Nicholls, Kathleen

AU - Sunder-Plassmann, Gere

AU - Jovanovic, Ana

AU - Feldt-Rasmussen, Ulla

AU - Schiffmann, Raphael

AU - Giugliani, Robert

AU - Jain, Vipul

AU - Viereck, Chris

AU - Castelli, Jeffrey P

AU - Skuban, Nina

AU - Barth, Jay A

AU - Bichet, Daniel G

PY - 2019/6

Y1 - 2019/6

U2 - 10.1002/ajmg.a.61105

DO - 10.1002/ajmg.a.61105

M3 - Journal article

C2 - 30920142

SN - 1552-4825

VL - 179

SP - 1069

EP - 1073

JO - American Journal of Medical Genetics. Part A

JF - American Journal of Medical Genetics. Part A

IS - 6

ER -